Clinical Trial Detail

NCT ID NCT03248479
Title Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Forty Seven, Inc.
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Azacitidine + Hu5F9-G4

Hu5F9-G4

Age Groups: adult senior

No variant requirements are available.